FibroBiologics (FBLG)
Develops allogeneic fibroblast therapies for diabetic foot ulcers and other chronic diseases.
Something off on this page? Send us feedback.
Develops allogeneic human fibroblast therapies and derived materials for chronic disease, with CYWC628 in a controlled human trial for refractory diabetic foot ulcers. The pre-revenue business is financed through debt and equity, while trials, cell supply and potential commercialization rely substantially on outside partners.
Develops allogeneic human fibroblast therapies and fibroblast-derived materials. CYWC628, a topical spheroid therapy for refractory diabetic foot ulcers, is in an active controlled trial in Australia; CYPS317 targets psoriasis, CYMS101 targets multiple sclerosis, and CybroCell targets degenerative disc disease.
Prioritizes disease areas with unmet need, combines internal preclinical work with CRO-run trials and CDMO-produced cell supply, and builds patent coverage around the platform. Houston hosts corporate operations and laboratory activity, while the Australian subsidiary sponsors the wound trial.
No products are approved, product sales do not fund operations, and any commercialization would require collaborators or new internal infrastructure. The U.S. FDA is the principal regulatory pathway for the other named programs, and third-party manufacturing dependence is expected to continue for the foreseeable future.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Aug 4, 2026 | Deutsche Bank | Downgrade | Underperform | |
| May 4, 2026 | Maxim Group | Downgrade | Buy | Hold |
| Mar 26, 2026 | D. Boral Capital | Downgrade | Buy | Hold |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.5M · Total debt $1.5M · Total assets $7.9M · Shareholders' equity $4.6M
- Revenue
- $0
- Operating income
- −$4.0M
- Net income
- −$4.1M
No dividends on record.
| Institutions17 holders · as of Mar 31, 2026 | 3.31% | 220.7K shares | |
| Insiders4 holders · as of Mar 5, 2026 | 4.71% | 313.5K shares | |
| Strategic holders1 holder · as of Aug 14, 2026 | 11.10% | 739.0K shares | |
| Otherremainder | 80.88% | 5.39M shares |
6.66M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (6.66M in the company's Sep 3, 2026 report, 2.10M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCStrategic | 11.10% | 738,977 | 13Gfiled Aug 14, 2026 ↗ |
Pete O'HeeronInsiderdirector, officer: CHIEF EXECUTIVE OFFICER | 4.47% | 297,907 | Form 4filed Mar 4, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 1.02% | 67,665 | 13Fas of Mar 31, 2026 |
Fund Evaluation Group, LLCInstitution | 0.78% | 51,794 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.44% | 29,609 | 13Fas of Mar 31, 2026 |
| See all 23 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 4, 2026 | Hamid Khoja | officer: Chief Scientific Officer | +30,000 | $0.3800 |
| Mar 2, 2026 | Pete O'Heeron | director, officer: CHIEF EXECUTIVE OFFICER | +17,428 | $0.3530 |
| Mar 3, 2026 | Pete O'Heeron | director, officer: CHIEF EXECUTIVE OFFICER | +18,200 | $0.4051 |
| Mar 4, 2026 | Pete O'Heeron | director, officer: CHIEF EXECUTIVE OFFICER | +15,872 | $0.3784 |
| Mar 2, 2026 | Jason Davis | officer: Chief Financial Officer | +70,000 | $0.4139 |
- Organogenesis
Direct DFU competitor with commercial living skin substitutes.
- Mesoblast (ADR)
Closest cell-therapy rival in degenerative disc disease.
- Novartis (ADR)
Large branded competitor across MS and psoriasis.
- Biogen
Established MS franchise with disease-modifying therapies.
- AbbVie
Leading psoriasis brands compete for systemic-treatment patients.
- Smith & Nephew (ADR)
Advanced wound devices and skin substitutes contest chronic-wound care.
- Bristol-Myers Squibb
Sotyktu is an approved oral competitor in plaque psoriasis.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| FibroBiologics | $1.93 | −0.49% | $4.1M | — | — | — | — |
| Organogenesis | $1.68 | +0.56% | $214.9M | — | — | 0.5 | −56.7% |
| Mesoblast (ADR) | $17.14 | −0.81% | $2.24B | — | — | 33.9 | +882.8% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Smith & Nephew (ADR) | $28.58 | −0.34% | $12.04B | 19.0 | — | 1.9 | +3.7% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Median | 24.5 | 17.0 | 3.3 | +3.7% |